Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong SAR, China.
Ir J Med Sci. 2009 Jun;178(2):173-8. doi: 10.1007/s11845-009-0291-y. Epub 2009 Feb 17.
Orlistat is a gastrointestinal lipase inhibitor approved for use in obesity. So far, no evidence has been reported on the use of orlistat in obese patients with coronary artery disease (CAD).
To investigate the effect of orlistat on body weight and lipid profiles in obese patients with CAD and hypercholesterolemia.
Thirty non-diabetic patients with CAD, body mass index (BMI) > or = 25 kg/m(2) and low-density lipoprotein cholesterol (LDL-C) > or = 2.6 and < 4.1 mmol/L were put on diet for 12 weeks. Those still having a BMI > or = 25 kg/m(2) received orlistat 120 mg thrice daily for another 24 weeks.
BMI was significantly reduced by 1.7% after 12 weeks of dietary treatment. The 24-week orlistat treatment resulted in further significant reduction in BMI (-2.8%) and LDL-C (-7.0%).
Diet and orlistat treatment significantly reduced BMI and improved LDL-C in obese patients with CAD and hypercholesterolemia.
奥利司他是一种胃肠道脂肪酶抑制剂，已被批准用于肥胖症的治疗。目前，尚未有关于奥利司他在伴有冠状动脉疾病（CAD）的肥胖患者中应用的报道。
研究奥利司他对伴有 CAD 和高胆固醇血症的肥胖患者体重和血脂谱的影响。
30 例非糖尿病 CAD 患者，体重指数（BMI）>或=25 kg/m(2)且低密度脂蛋白胆固醇（LDL-C）>或=2.6 且<4.1 mmol/L，进行 12 周饮食治疗。那些 BMI>或=25 kg/m(2)的患者继续接受奥利司他 120 mg，每日 3 次，治疗 24 周。
饮食治疗 12 周后 BMI 显著降低 1.7%。24 周的奥利司他治疗使 BMI（-2.8%）和 LDL-C（-7.0%）进一步显著降低。
饮食和奥利司他治疗可显著降低伴有 CAD 和高胆固醇血症的肥胖患者的 BMI 并改善 LDL-C。
Zotero 插件